Does the media favor TECX or SRPT?

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Sarepta Therapeutics' score of 0.70 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Sarepta Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is TECX or PVLA more profitable?

Tectonic Therapeutic's return on equity of -35.26% beat Palvella Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Tectonic Therapeutic N/A -35.26% -33.59% Palvella Therapeutics N/A -47.84% -38.33%

Does the media favor TECX or PVLA?

In the previous week, Palvella Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for Palvella Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Palvella Therapeutics' score of 0.64 indicating that Tectonic Therapeutic is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Palvella Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to TECX or BCRX?

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Tectonic Therapeutic. BioCryst Pharmaceuticals' average media sentiment score of 1.12 beat Tectonic Therapeutic's score of 0.88 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive BioCryst Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to NUVB or TECX?

In the previous week, Nuvation Bio had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Nuvation Bio and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Nuvation Bio's score of 0.59 indicating that Tectonic Therapeutic is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Nuvation Bio 3 Very Positive mention(s) 1 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Tectonic Therapeutic 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Tectonic Therapeutic (TECX) Competitors

$24.98 -1.52 (-5.74%)

Closing price 09/23/2026 04:00 PM Eastern

Extended Trading

$24.92 -0.06 (-0.23%)

As of 04:10 AM Eastern

Compare

TECX vs. SRPT, PVLA, AUPH, BCRX, and NUVB

Should you buy Tectonic Therapeutic stock or one of its competitors? Tectonic Therapeutic's main competitors and comparable companies include Sarepta Therapeutics (SRPT), Palvella Therapeutics (PVLA), Aurinia Pharmaceuticals (AUPH), BioCryst Pharmaceuticals (BCRX), and Nuvation Bio (NUVB). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Tectonic Therapeutic (NASDAQ:TECX) and Sarepta Therapeutics (NASDAQ:SRPT) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, earnings, profitability, valuation, dividends and risk.

Tectonic Therapeutic has a net margin of 0.00% compared to Sarepta Therapeutics' net margin of -13.48%. Sarepta Therapeutics' return on equity of -1.60% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Sarepta Therapeutics	-13.48%	-1.60%	-0.66%

Tectonic Therapeutic presently has a consensus target price of $77.25, indicating a potential upside of 209.25%. Sarepta Therapeutics has a consensus target price of $24.07, indicating a potential upside of 27.00%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities analysts clearly believe Tectonic Therapeutic is more favorable than Sarepta Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Sarepta Therapeutics	6 Sell rating(s)	5 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.11

Tectonic Therapeutic has higher earnings, but lower revenue than Sarepta Therapeutics. Sarepta Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Sarepta Therapeutics	$2.20B	0.91	-$713.41M	-$2.90	N/A

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 86.7% of Sarepta Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 6.9% of Sarepta Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market. Comparatively, Sarepta Therapeutics has a beta of 0.27, suggesting that its share price is 73% less volatile than the broader market.

In the previous week, Sarepta Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for Sarepta Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Sarepta Therapeutics' score of 0.70 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Sarepta Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Sarepta Therapeutics on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Tectonic Therapeutic (NASDAQ:TECX) and Palvella Therapeutics (NASDAQ:PVLA) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their earnings, valuation, dividends, risk, profitability, analyst recommendations, media sentiment and institutional ownership.

Tectonic Therapeutic has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, Palvella Therapeutics has a beta of -0.25, meaning that its share price is 125% less volatile than the broader market.

Palvella Therapeutics has higher revenue and earnings than Tectonic Therapeutic. Palvella Therapeutics is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Palvella Therapeutics	$42.81M	50.34	-$41.72M	-$4.83	N/A

Tectonic Therapeutic currently has a consensus price target of $77.25, indicating a potential upside of 209.25%. Palvella Therapeutics has a consensus price target of $209.14, indicating a potential upside of 39.84%. Given Tectonic Therapeutic's higher possible upside, equities research analysts clearly believe Tectonic Therapeutic is more favorable than Palvella Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Palvella Therapeutics	1 Sell rating(s)	0 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.93

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 40.1% of Palvella Therapeutics shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 17.2% of Palvella Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tectonic Therapeutic's return on equity of -35.26% beat Palvella Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Palvella Therapeutics	N/A	-47.84%	-38.33%

In the previous week, Palvella Therapeutics had 3 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 5 mentions for Palvella Therapeutics and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Palvella Therapeutics' score of 0.64 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Palvella Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Summary

Tectonic Therapeutic beats Palvella Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Tectonic Therapeutic (NASDAQ:TECX) and Aurinia Pharmaceuticals (NASDAQ:AUPH) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 36.8% of Aurinia Pharmaceuticals shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by insiders. Comparatively, 10.4% of Aurinia Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Tectonic Therapeutic has a beta of 3.31, suggesting that its share price is 231% more volatile than the broader market. Comparatively, Aurinia Pharmaceuticals has a beta of 1.4, suggesting that its share price is 40% more volatile than the broader market.

Aurinia Pharmaceuticals has a net margin of 100.84% compared to Tectonic Therapeutic's net margin of 0.00%. Aurinia Pharmaceuticals' return on equity of 26.11% beat Tectonic Therapeutic's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
Aurinia Pharmaceuticals	100.84%	26.11%	19.89%

Aurinia Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. Tectonic Therapeutic is trading at a lower price-to-earnings ratio than Aurinia Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
Aurinia Pharmaceuticals	$283.05M	7.71	$287.20M	$2.29	7.16

In the previous week, Tectonic Therapeutic had 2 more articles in the media than Aurinia Pharmaceuticals. MarketBeat recorded 2 mentions for Tectonic Therapeutic and 0 mentions for Aurinia Pharmaceuticals. Tectonic Therapeutic's average media sentiment score of 0.88 beat Aurinia Pharmaceuticals' score of 0.57 indicating that Tectonic Therapeutic is being referred to more favorably in the media.

Company	Overall Sentiment
Tectonic Therapeutic	Positive
Aurinia Pharmaceuticals	Positive

Tectonic Therapeutic presently has a consensus target price of $77.25, indicating a potential upside of 209.25%. Aurinia Pharmaceuticals has a consensus target price of $17.67, indicating a potential upside of 7.72%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, equities analysts plainly believe Tectonic Therapeutic is more favorable than Aurinia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
Aurinia Pharmaceuticals	0 Sell rating(s)	3 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.67

Summary

Tectonic Therapeutic beats Aurinia Pharmaceuticals on 9 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

Tectonic Therapeutic (NASDAQ:TECX) and BioCryst Pharmaceuticals (NASDAQ:BCRX) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk, media sentiment and institutional ownership.

Tectonic Therapeutic has a net margin of 0.00% compared to BioCryst Pharmaceuticals' net margin of -40.90%. Tectonic Therapeutic's return on equity of -35.26% beat BioCryst Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Tectonic Therapeutic	N/A	-35.26%	-33.59%
BioCryst Pharmaceuticals	-40.90%	-86.89%	66.37%

Tectonic Therapeutic currently has a consensus price target of $77.25, suggesting a potential upside of 209.25%. BioCryst Pharmaceuticals has a consensus price target of $20.40, suggesting a potential upside of 138.04%. Given Tectonic Therapeutic's stronger consensus rating and higher probable upside, equities research analysts plainly believe Tectonic Therapeutic is more favorable than BioCryst Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88
BioCryst Pharmaceuticals	1 Sell rating(s)	4 Hold rating(s)	7 Buy rating(s)	0 Strong Buy rating(s)	2.50

Tectonic Therapeutic has a beta of 3.31, meaning that its share price is 231% more volatile than the broader market. Comparatively, BioCryst Pharmaceuticals has a beta of 0.57, meaning that its share price is 43% less volatile than the broader market.

In the previous week, BioCryst Pharmaceuticals had 2 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 4 mentions for BioCryst Pharmaceuticals and 2 mentions for Tectonic Therapeutic. BioCryst Pharmaceuticals' average media sentiment score of 1.12 beat Tectonic Therapeutic's score of 0.88 indicating that BioCryst Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
BioCryst Pharmaceuticals	3 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

62.6% of Tectonic Therapeutic shares are owned by institutional investors. Comparatively, 85.9% of BioCryst Pharmaceuticals shares are owned by institutional investors. 39.8% of Tectonic Therapeutic shares are owned by company insiders. Comparatively, 3.8% of BioCryst Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

BioCryst Pharmaceuticals has higher revenue and earnings than Tectonic Therapeutic. BioCryst Pharmaceuticals is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A
BioCryst Pharmaceuticals	$874.84M	2.50	$263.86M	-$1.50	N/A

Summary

Tectonic Therapeutic and BioCryst Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Tectonic Therapeutic compare to Nuvation Bio?

Nuvation Bio (NYSE:NUVB) and Tectonic Therapeutic (NASDAQ:TECX) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, earnings, analyst recommendations, risk, valuation, dividends, media sentiment and institutional ownership.

In the previous week, Nuvation Bio had 6 more articles in the media than Tectonic Therapeutic. MarketBeat recorded 8 mentions for Nuvation Bio and 2 mentions for Tectonic Therapeutic. Tectonic Therapeutic's average media sentiment score of 0.88 beat Nuvation Bio's score of 0.59 indicating that Tectonic Therapeutic is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nuvation Bio	3 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Tectonic Therapeutic	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Tectonic Therapeutic has lower revenue, but higher earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Tectonic Therapeutic, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nuvation Bio	$169.90M	11.77	-$204.63M	-$0.44	N/A
Tectonic Therapeutic	N/A	N/A	-$74.15M	-$4.57	N/A

Nuvation Bio has a beta of 1.52, indicating that its stock price is 52% more volatile than the broader market. Comparatively, Tectonic Therapeutic has a beta of 3.31, indicating that its stock price is 231% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 62.6% of Tectonic Therapeutic shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by company insiders. Comparatively, 39.8% of Tectonic Therapeutic shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Tectonic Therapeutic has a net margin of 0.00% compared to Nuvation Bio's net margin of -88.18%. Tectonic Therapeutic's return on equity of -35.26% beat Nuvation Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nuvation Bio	-88.18%	-46.59%	-22.01%
Tectonic Therapeutic	N/A	-35.26%	-33.59%

Nuvation Bio presently has a consensus price target of $13.00, suggesting a potential upside of 128.27%. Tectonic Therapeutic has a consensus price target of $77.25, suggesting a potential upside of 209.25%. Given Tectonic Therapeutic's stronger consensus rating and higher possible upside, analysts plainly believe Tectonic Therapeutic is more favorable than Nuvation Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nuvation Bio	1 Sell rating(s)	2 Hold rating(s)	10 Buy rating(s)	0 Strong Buy rating(s)	2.69
Tectonic Therapeutic	1 Sell rating(s)	1 Hold rating(s)	4 Buy rating(s)	2 Strong Buy rating(s)	2.88

Summary

Tectonic Therapeutic beats Nuvation Bio on 11 of the 16 factors compared between the two stocks.

Get Tectonic Therapeutic News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TECX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TECX vs. The Competition

Export

Metric	Tectonic Therapeutic	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$518.06M	$3.98B	$7.31B	$13.29B
Dividend Yield	N/A	3.63%	2.52%	12.57%
P/E Ratio	-5.47	13.88	274.08	25.69
Price / Sales	N/A	1,343.77	638.21	78.99
Price / Cash	N/A	113.29	77.80	52.76
Price / Book	1.86	15.40	10.47	6.32
Net Income	-$74.15M	-$22.82M	$3.49B	$359.73M
7 Day Performance	-8.20%	-1.70%	-0.67%	0.17%
1 Month Performance	-31.51%	-6.17%	-3.17%	-3.27%
1 Year Performance	66.64%	30.67%	15.14%	5.58%

Tectonic Therapeutic Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TECX Tectonic Therapeutic	2.8656 of 5 stars	$24.98 -5.7%	$77.25 +209.2%	+65.3%	$518.06M	N/A	N/A	60
SRPT Sarepta Therapeutics	3.6236 of 5 stars	$20.72 -1.0%	$25.69 +24.0%	+5.7%	$2.21B	$1.97B	N/A	835
PVLA Palvella Therapeutics	2.4804 of 5 stars	$151.22 -0.3%	$209.14 +38.3%	+163.8%	$2.19B	$42.81M	N/A	29	Analyst Forecast
AUPH Aurinia Pharmaceuticals	3.3315 of 5 stars	$16.13 -1.7%	$17.67 +9.5%	+26.2%	$2.18B	$283.05M	7.04	128
BCRX BioCryst Pharmaceuticals	2.4295 of 5 stars	$8.16 -0.9%	$20.40 +150.0%	+9.6%	$2.10B	$940.61M	N/A	435	Positive News Analyst Downgrade

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TECX) was last updated on 9/24/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Tectonic Therapeutic (TECX) Competitors

TECX vs. SRPT, PVLA, AUPH, BCRX, and NUVB

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Summary

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Summary

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

Summary

How does Tectonic Therapeutic compare to Nuvation Bio?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Tectonic Therapeutic (TECX) Competitors

TECX vs. SRPT, PVLA, AUPH, BCRX, and NUVB

How does Tectonic Therapeutic compare to Sarepta Therapeutics?

Is TECX or SRPT more profitable?

Do analysts rate TECX or SRPT?

Which has better earnings and valuation, TECX or SRPT?

Do institutionals and insiders believe in TECX or SRPT?

Which has more volatility & risk, TECX or SRPT?

Does the media favor TECX or SRPT?

Summary

How does Tectonic Therapeutic compare to Palvella Therapeutics?

Which has more volatility and risk, TECX or PVLA?

Which has preferable earnings & valuation, TECX or PVLA?

Do analysts prefer TECX or PVLA?

Do institutionals and insiders have more ownership in TECX or PVLA?

Is TECX or PVLA more profitable?

Does the media favor TECX or PVLA?

Summary

How does Tectonic Therapeutic compare to Aurinia Pharmaceuticals?

Do insiders & institutionals believe in TECX or AUPH?

Which has more volatility and risk, TECX or AUPH?

Is TECX or AUPH more profitable?

Which has better valuation and earnings, TECX or AUPH?

Does the media refer more to TECX or AUPH?

Do analysts rate TECX or AUPH?

Summary

How does Tectonic Therapeutic compare to BioCryst Pharmaceuticals?

Is TECX or BCRX more profitable?

Do analysts prefer TECX or BCRX?

Which has more risk & volatility, TECX or BCRX?

Does the media refer more to TECX or BCRX?

Do insiders & institutionals have more ownership in TECX or BCRX?

Which has preferable valuation & earnings, TECX or BCRX?

Summary

How does Tectonic Therapeutic compare to Nuvation Bio?

Does the media refer more to NUVB or TECX?

Which has higher valuation and earnings, NUVB or TECX?

Which has more volatility and risk, NUVB or TECX?

Do institutionals & insiders have more ownership in NUVB or TECX?

Is NUVB or TECX more profitable?

Do analysts rate NUVB or TECX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TECX vs. The Competition

Tectonic Therapeutic Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools